Simbec-Orion
Rubaljeet Tatla is an experienced professional in pharmacovigilance, currently serving as the Head of Pharmacovigilance at Simbec-Orion since July 2023. Prior experience includes roles as Associate Director of Safety and Pharmacovigilance at Syneos Health from October 2021 to June 2023, and Manager of Drug Safety Center at PRA Health Sciences from December 2016 to September 2021, where oversight of drug safety processes for Takeda Pharmaceuticals was provided. Additional positions include Pharmacovigilance roles at Takeda from October 2013 to December 2016, and a Speech and Language Assistant at Berkshire Healthcare NHS Foundation Trust from December 2012 to October 2013. Rubaljeet Tatla holds a degree in Biomedical Science from Brunel University London, obtained between 2010 and 2013.
This person is not in any offices
Simbec-Orion
2 followers
Simbec-Orion is a responsive and agile full-service CRO, with wide therapeutic experience and specialist expertise in clinical pharmacology, oncology and rare diseases. Structured to adapt quickly, we provide full-service clinical development solutions for small and mid-size drug developers – headed up by a centralised leadership team. With a focus on tailormade and scalable solutions, we’ll match our delivery style, communications and operations to suit the demands of your project, helping you achieve your clinical and commercial objectives. Because our goal is the same as yours; to improve patients’ lives.